NDT_A_219962 2893..2900

Jing Lu Shangda Li 1 Haimei Li Tingting Mou Lihong Zhou Bochao Huang Manli Huang Yi Xu 1The Key Laboratory of Mental Disorder Management in Zhejiang Province, Department of Psychiatry, First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang University Brain Research Institute, Hangzhou, Zhejiang Province, People’s Republic of China; 2Institute of Criminal Science and Technology, Hangzhou Public Security Bureau, Hangzhou, Zhejiang Province, People’s Republic of China Purpose: There is growing evidence showing that inflammatory cytokines and neuropeptides may be involved in the pathophysiology of suicidal behavior. However, studies have yielded contradictory data, and no biological markers that help predict suicide have been identified. This study aimed to identify biological patterns, such as NPY, IL-1β and hypocretin plasma levels, in people who died by suicide. Patients and methods: Twenty-two people who died by suicide compared with 22 controls matched for age and sex were studied. In suicide and control subjects, we estimated the levels of NPY, IL-1β and hypocretin in plasma using enzyme-linked immunosorbent assay. The data are presented as the median (25th–75th percentile). Results: We found (1) a significant elevation in plasma NPY levels in suicide subjects versus control subjects (suicide: 11.38 (9.380–16.55); controls: 8.95 (7.590–10.93); P=0.013), and plasma NPY concentrations were approximately 62% higher in suicide subjects than those in control subjects; (2) a significant decrease in plasma IL-1β concentrations between suicide and control subjects (suicide: 121.1 (82.97–143.0); controls: 425.9 (233.1–835.3); P<0.001) as well as a decrease in IL-1β concentrations by almost 80%; and (3) no significant difference in plasma hypocretin levels between suicide and control subjects (suicide: 16.62 (13.62–25.77); controls: 21.63 (14.97–29.72); P=0.356). Conclusion: Our results suggest that plasma NPY and IL-1β were related with suicide behavior rather than to suicide causes or suicide method. Specific combinations of plasma biomarkers may discriminate between types of suicidal behaviors and indicate increased risk for future suicide attempts.

[1]  R. Lu,et al.  Differences in immunomodulatory properties between venlafaxine and paroxetine in patients with major depressive disorder , 2018, Psychoneuroendocrinology.

[2]  C. Jia,et al.  Psychological and behavioral characteristics of suicide attempts and non-suicidal self-injury in Chinese adolescents. , 2018, Journal of affective disorders.

[3]  T. Nakamachi,et al.  Neuropeptide Y-Induced Orexigenic Action Is Attenuated by the Orexin Receptor Antagonist in Bullfrog Larvae , 2017, Front. Neurosci..

[4]  D. Swaab,et al.  Sexually Dimorphic Changes of Hypocretin (Orexin) in Depression , 2017, EBioMedicine.

[5]  M. Laudenslager,et al.  Blunted HPA axis activity prior to suicide attempt and increased inflammation in attempters , 2017, Psychoneuroendocrinology.

[6]  D. Şahin,et al.  The effect of leptin, ghrelin, and neuropeptide-Y on serum Tnf-Α, Il-1β, Il-6, Fgf-2, galanin levels and oxidative stress in an experimental generalized convulsive seizure model , 2017, Neuropeptides.

[7]  J. Herman,et al.  Neuropeptide Y (NPY) and posttraumatic stress disorder (PTSD): A translational update , 2016, Experimental Neurology.

[8]  J. Mann,et al.  The role of cytokines in the pathophysiology of suicidal behavior , 2016, Psychoneuroendocrinology.

[9]  S. Ozsoy,et al.  The Effects of Antidepressants on Neuropeptide Y in Patients with Depression and Anxiety , 2016, Pharmacopsychiatry.

[10]  S. Patterson.  Immune dysregulation and cognitive vulnerability in the aging brain: Interactions of microglia, IL-1β, BDNF and synaptic plasticity , 2015, Neuropharmacology.

[11]  H. Hwu,et al.  Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms , 2015, Psychoneuroendocrinology.

[12]  J. Malm,et al.  Suicidal patients are deficient in vitamin D, associated with a pro-inflammatory status in the blood , 2014, Psychoneuroendocrinology.

[13]  L. Quevedo,et al.  Immune dysfunction in bipolar disorder and suicide risk: is there an association between peripheral corticotropin-releasing hormone and interleukin-1β? , 2014, Bipolar disorders.

[14]  J. Mann,et al.  Life Events: A Complex Role In The Timing Of Suicidal Behavior Among Depressed Patients , 2013, Molecular Psychiatry.

[15]  Yogesh K. Dwivedi,et al.  The Role of Neuropeptides in Suicidal Behavior: A Systematic Review , 2013, BioMed research international.

[16]  M. Netea,et al.  New Insights in the Immunobiology of IL-1 Family Members , 2013, Front. Immunol..

[17]  M. Nollet,et al.  Role of Orexin in the Pathophysiology of Depression: Potential for Pharmacological Intervention , 2013, CNS Drugs.

[18]  M. Fornaro,et al.  Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds. , 2013, Journal of affective disorders.

[19]  E. Coccaro,et al.  Cerebrospinal Fluid Neuropeptide Y-like Immunoreactivity Correlates with Impulsive Aggression in Human Subjects , 2012, Biological Psychiatry.

[20]  U. Hegerl,et al.  CSF-hypocretin-1 levels in patients with major depressive disorder compared to healthy controls , 2011, Psychiatry Research.

[21]  J. Malva,et al.  Neuropeptide Y inhibits interleukin-1β-induced phagocytosis by microglial cells , 2011, Journal of Neuroinflammation.

[22]  J. Treasure,et al.  Experimental measurement of the regulation of anger and aggression in women with anorexia nervosa. , 2011, Clinical psychology & psychotherapy.

[23]  D. Marks,et al.  Inflammation-Induced Lethargy Is Mediated by Suppression of Orexin Neuron Activity , 2011, The Journal of Neuroscience.

[24]  W. Gattaz,et al.  Body Mass Index Increase, Serum Leptin, Adiponectin, Neuropeptide Y and Lipid Levels during Treatment with Olanzapine and Haloperidol , 2011, Pharmacopsychiatry.

[25]  M. Hoptman,et al.  Self-report and laboratory measures of impulsivity in patients with schizophrenia or schizoaffective disorder and healthy controls , 2011, Psychiatry Research.

[26]  J. Babb,et al.  A preliminary study of cytokines in suicidal and nonsuicidal adolescents with major depression. , 2009, Journal of child and adolescent psychopharmacology.

[27]  L. Träskman-bendz,et al.  Increased orexin levels in the cerebrospinal fluid the first year after a suicide attempt. , 2009, Journal of affective disorders.

[28]  D. Rujescu,et al.  Elevated cytokine expression in the orbitofrontal cortex of victims of suicide , 2008, Acta psychiatrica Scandinavica.

[29]  L. Träskman-bendz,et al.  Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder , 2007, European Neuropsychopharmacology.

[30]  L. Träskman-bendz,et al.  Orexin and psychiatric symptoms in suicide attempters. , 2007, Journal of affective disorders.

[31]  J. Harro.  CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies , 2006, Amino Acids.

[32]  S. Kanai,et al.  Differences in the Appetite-Stimulating Effect of Orexin, Neuropeptide Y and Ghrelin among Young, Adult and Old Rats , 2006, Neuroendocrinology.

[33]  A. Baranowska-Bik,et al.  Plasma orexin A, orexin B, leptin, neuropeptide Y (NPY) and insulin in obese women. , 2005, Neuro endocrinology letters.

[34]  A. N. van den Pol,et al.  Neuropeptide Y Inhibits Hypocretin/Orexin Neurons by Multiple Presynaptic and Postsynaptic Mechanisms: Tonic Depression of the Hypothalamic Arousal System , 2004, The Journal of Neuroscience.

[35]  M. Åsberg,et al.  Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. , 2004, Journal of psychiatric research.

[36]  G. Telegdy,et al.  The role of NPY in the mediation of orexin-induced hypothermia , 2002, Regulatory Peptides.

[37]  H. Volkoff,et al.  Interactions between orexin A, NPY and galanin in the control of food intake of the goldfish, Carassius auratus , 2001, Regulatory Peptides.

[38]  M. Ghatei,et al.  The Central Effects of Orexin‐A in the Hypothalamic‐Pituitary‐Adrenal Axis In Vivo and In Vitro in Male Rats , 2001, Journal of neuroendocrinology.

[39]  J. Turchan,et al.  Effects of acute or long-term treatment with chlorpromazine, haloperidol or sulpiride on neuropeptide Y-like immunoreactivity concentrations in the nucleus accumbens of rat , 1999, European Neuropsychopharmacology.

[40]  G. Ordway,et al.  Reduced Neuropeptide Y Concentrations in Suicide Brain , 1992, Journal of neurochemistry.

[41]  I. Grant,et al.  Neuropeptide Y and natural killer cell activity: findings in depression and Alzheimer caregiver stress , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  J. Gelernter,et al.  Neuropeptide Y-like immunoreactivity in schizophrenia Relationships with clinical measures , 1990, Schizophrenia Research.

[43]  M. Åsberg,et al.  Monoamine metabolites in CSF and suicidal behavior. , 1981, Archives of general psychiatry.

[44]  G. Pandey.  Inflammatory and Innate Immune Markers of Neuroprogression in Depressed and Teenage Suicide Brain. , 2017, Modern trends in pharmacopsychiatry.

[45]  Yogesh K. Dwivedi,et al.  Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. , 2012, Journal of psychiatric research.

[46]  M. Netea,et al.  The effects of dexamethasone and chlorpromazine on tumour necrosis factor-alpha, interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-10 in human volunteers. , 1997, Immunology.

[47]  A. Roy.  Neuropeptides in relation to suicidal behavior in depression. , 1993, Neuropsychobiology.

[48]  C. Wahlestedt,et al.  Origin and Actions of Neuropeptide Y in the Cardiovascular System , 1993 .